-

$undefined

N/A

(N/A)

Immunovant NasdaqGS:IMVT Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Location: 320 West 37th Street, New York, NY, 10018, United States | Website: https://immunovant.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.903B

Cash

714M

Avg Qtr Burn

-93.97M

Short % of Float

34.27%

Insider Ownership

58.37%

Institutional Own.

55.82%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Batoclimab (IMVT-1401) Details Thyroid Eye Disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batoclimab (IMVT-1401) Details Myasthenia gravis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batoclimab (IMVT-1401) Details Graves’ disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMVT-1402 Details Rheumatoid arthritis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMVT-1402 Details Graves’ disease Suspected Mover™ Susp. Mover™	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batoclimab (IMVT-1401) Details Chronic inflammatory disorder	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMVT-1402 Details Sjögren’s Disease (SjD)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMVT-1402 Details Autoimmune disease, Warm autoimmune hemolytic anemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batoclimab (IMVT-1401) Details Warm autoimmune hemolytic anemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.